Skip to main content
An official website of the United States government

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Completed
NCT ID
NCT02365480
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer. Patients with ulcerative colitis are at increased risk for colorectal cancer. Chemoprevention is the use of drugs, such as berberine chloride, to keep a disease/condition from forming or coming back. The use of berberine chloride may keep colorectal cancer from forming in patients with ulcerative colitis.
Intervention
Berberine Chloride, Laboratory Biomarker Analysis, Placebo Administration
Condition
Ulcerative Colitis
Investigators
Kaichun Wu

See list of participating sites